Compare TAL & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAL | CRSP |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.8B |
| IPO Year | 2010 | 2016 |
| Metric | TAL | CRSP |
|---|---|---|
| Price | $12.38 | $55.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 17 |
| Target Price | $11.15 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 3.7M | 1.3M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | $22.97 | $807.72 |
| Revenue Next Year | $17.08 | $172.52 |
| P/E Ratio | $23.36 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $8.88 | $44.12 |
| 52 Week High | $13.37 | $78.48 |
| Indicator | TAL | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 52.29 |
| Support Level | $10.70 | $50.45 |
| Resistance Level | $12.55 | $59.94 |
| Average True Range (ATR) | 0.38 | 2.72 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 70.22 | 41.78 |
TAL Education Group is a leading learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.